SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Sampson U))
 

Search: (WFRF:(Sampson U)) > (2020-2024) > Meta-analyses of at...

Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy

Campbell, C. (author)
Barohn, R. J. (author)
Bertini, E. (author)
show more...
Chabrol, B. (author)
Comi, G. P. (author)
Darras, B. T. (author)
Finkel, R. S. (author)
Flanigan, K. M. (author)
Goemans, N. (author)
Iannaccone, S. T. (author)
Karolinska Institutet
Jones, K. J. (author)
Kirschner, J. (author)
Mah, J. K. (author)
Mathews, K. D. (author)
McDonald, C. M. (author)
Mercuri, E. (author)
Nevo, Y. (author)
Pereon, Y. (author)
Ben Renfroe, J. (author)
Ryan, M. M. (author)
Sampson, J. B. (author)
Schara, U. (author)
Sejersen, T. (author)
Selby, K. (author)
Tulinius, Mar, 1953 (author)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
Vilchez, J. J. (author)
Voit, T. (author)
Wei, L. J. (author)
Wong, B. L. (author)
Elfring, G. (author)
Souza, M. (author)
McIntosh, J. (author)
Trifillis, P. (author)
Peltz, S. W. (author)
Muntoni, F. (author)
P. TC124-GD-007-Study Grp, P. TC124-GD-007-Study Grp (author)
Act Dmd Study Grp, Act Dmd Study Grp (author)
Clinical Evaluator Training, Grp (author)
show less...
 (creator_code:org_t)
Becaris Publishing Limited, 2020
2020
English.
In: Journal of Comparative Effectiveness Research. - : Becaris Publishing Limited. - 2042-6305 .- 2042-6313. ; 9:14
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Aim:Assess the totality of efficacy evidence for ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD).Materials & methods:Data from the two completed randomized controlled trials (ClinicalTrials.gov: NCT00592553; NCT01826487) of ataluren in nmDMD were combined to examine the intent-to-treat (ITT) populations and two patient subgroups (baseline 6-min walk distance [6MWD] >= 300-<400 or <400 m). Meta-analyses examined 6MWD change from baseline to week 48.Results:Statistically significant differences in 6MWD change with ataluren versus placebo were observed across all three meta-analyses. Least-squares mean difference (95% CI): ITT (n = 342), +17.2 (0.2-34.1) m, p = 0.0473; >= 300-<400 m (n = 143), +43.9 (18.2-69.6) m, p = 0.0008; <400 m (n = 216), +27.7 (6.4-49.0) m, p = 0.0109.Conclusion:These meta-analyses support previous evidence for ataluren in slowing disease progression versus placebo in patients with nmDMD over 48 weeks. Treatment benefit was most evident in patients with a baseline 6MWD >= 300-<400 m (the ambulatory transition phase), thereby informing future trial design.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Annan medicin och hälsovetenskap (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Other Medical and Health Sciences (hsv//eng)

Keyword

6-minute walk distance
ataluren
Duchenne muscular dystrophy
efficacy
meta-analyses
nonsense mutation Duchenne muscular dystrophy
randomized
controlled trials
6-minute walk test
end-points
multicenter
Health Care Sciences & Services

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view